NCT04372641 2025-09-17
Testing the Safety of CB-5339 in Patients With Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
Clinical Trials
33 trialsNCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn
NCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT06365918 2025-02-17
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05653661 2025-01-07
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic
Phase 1 Withdrawn
NCT05678283 2024-04-17
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT01632436 2023-10-02
Hepatic
CTI BioPharma
Phase 1 Withdrawn
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT05729139 2023-08-09
Cemiplimab/Peg-Interferon-α in Advanced CSCC
Baptist Health South Florida
Phase 1 Withdrawn
NCT03906643 2022-12-20
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies
Duke University
Phase 1 Withdrawn
NCT05253105 2022-05-31
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Withdrawn
NCT04315155 2020-10-28
BENEFIT
University of Utah
Phase 1 Withdrawn
NCT03606655 2020-01-13
Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK
University of Florida
Phase 1 Withdrawn
NCT03652233 2019-06-20
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02939846 2018-09-14
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
Phase 1 Withdrawn
NCT02674555 2017-07-28
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT02723838 2017-03-07
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Oncolytics Biotech
Phase 1 Withdrawn
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT00627835 2016-07-20
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
British Columbia Cancer Agency
Phase 1 Withdrawn
NCT02292732 2016-01-26
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT00534807 2015-09-01
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00666081 2015-04-17
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
GlaxoSmithKline
Phase 1 Withdrawn
NCT00024674 2014-11-14
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
INSYS Therapeutics Inc
Phase 1 Withdrawn
NCT00024687 2014-11-14
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
INSYS Therapeutics Inc
Phase 1 Withdrawn
NCT01567384 2013-11-20
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Emory University
Phase 1 Withdrawn
NCT01437280 2013-08-14
GOAT
Baylor College of Medicine
Phase 1 Withdrawn
NCT01031212 2013-05-13
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
University of California, San Francisco
Phase 1 Withdrawn
NCT00935142 2013-01-25
[18F]VM4-037
Maastricht Radiation Oncology
Phase 1 Withdrawn
NCT01491139 2012-05-30
ORCA
University College, London
Phase 1 Withdrawn
NCT00442741 2012-04-25
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
Novartis
Phase 1 Withdrawn
NCT01146171 2012-02-07
Japanese Phase 1 Study of BMS-844203 (CT322)
Bristol-Myers Squibb
Phase 1 Withdrawn